Shirong Liu

6PUBLICATIONS
23CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 08, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.

|Apr 15, 2026
Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.

|Mar 15, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.

Jorge J Castillo, Andrew R Branagan, Alberto Guijosa

|Feb 11, 2026
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.

Hao Sun, Romanos Sklavenitis Pistofidis, Shirong Liu

|Nov 19, 2025
Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia.

Shirong Liu, Amanda Kofides, Xia Liu

|Apr 20, 2025
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemia.

Shirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf

Pageof 1

Frequent Collaborators

6 joint publications

Zachary R Hunter

6 joint publications

Steven P Treon

5 joint publications

Jorge J Castillo

4 joint publications

Maria Luisa Guerrera